Athersys, Inc. (NASDAQ:ATHX) insider William Lehmann, Jr. sold 15,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The stock was sold at an average price of $2.38, for a total value of $35,700.00. Following the transaction, the insider now owns 527,380 shares in the company, valued at $1,255,164.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Athersys, Inc. (ATHX) traded up 2.02% on Friday, reaching $2.52. The company had a trading volume of 281,096 shares. Athersys, Inc. has a 12 month low of $1.02 and a 12 month high of $2.57. The firm’s 50 day moving average is $1.77 and its 200 day moving average is $1.54. The firm’s market capitalization is $287.06 million.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $0.96 million. Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.08) earnings per share. On average, equities research analysts expect that Athersys, Inc. will post ($0.24) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://ledgergazette.com/2017/09/22/athersys-inc-athx-insider-sells-35700-00-in-stock.html.
ATHX has been the topic of a number of analyst reports. Maxim Group set a $12.00 price target on Athersys and gave the company a “buy” rating in a report on Monday, August 7th. Zacks Investment Research upgraded Athersys from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Monday, August 14th. Finally, ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Athersys currently has an average rating of “Buy” and an average target price of $7.17.
A number of large investors have recently bought and sold shares of ATHX. Teachers Advisors LLC increased its holdings in Athersys by 21.9% in the fourth quarter. Teachers Advisors LLC now owns 156,880 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 28,178 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Athersys by 4.8% in the first quarter. Wells Fargo & Company MN now owns 61,176 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,800 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in Athersys by 11.1% in the first quarter. Bank of New York Mellon Corp now owns 265,165 shares of the biopharmaceutical company’s stock valued at $453,000 after buying an additional 26,526 shares during the last quarter. TFS Capital LLC purchased a new position in Athersys in the first quarter valued at $149,000. Finally, Vanguard Group Inc. increased its holdings in Athersys by 19.5% in the first quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after buying an additional 637,322 shares during the last quarter. 19.08% of the stock is currently owned by hedge funds and other institutional investors.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.